Montara Therapeutics, Inc.

Montara Therapeutics is a preclinical-stage biopharmaceutical company focused on developing safer and more effective treatments for neurological diseases. They are based in San Francisco and are developing a novel platform called BrainOnly™, which aims to prevent peripheral toxicities associated with neuroscience drugs, thereby enhancing safety and enabling the development of treatments for previously undruggable targets. BrainOnly™ works by using a two-drug combination therapy: a brain-penetrant, target-specific drug and a non-brain penetrant "universal" peripheral blocker. This approach ensures that the drug is only active in the brain, preventing harmful side effects in the rest of the body.

The company is founded by experienced biotech entrepreneurs, including Nicholas T. Hertz and Kevan Shokat, who have a successful track record in the field. Montara is backed by top-tier investors, including SV Health Investors’ Dementia Discovery Fund, Two Bear Capital, KdT Ventures, and Dolby Family Ventures. They are currently advancing their internal pipeline toward the clinic and also exploring partnerships to leverage their technology and bring safer and more effective therapies to patients suffering from brain disorders.

Montara Therapeutics is a preclinical-stage biopharmaceutical company dedicated to developing safer and more effective treatments for neurological diseases. Their mission is to revolutionize brain-targeting drug discovery and development through their proprietary BrainOnly™ platform. This platform addresses the critical challenge of dose-limiting peripheral toxicities, which often impede the development of promising neurological therapies. By preventing these toxicities and concentrating drug activity in the brain, Montara aims to unlock previously undruggable targets and bring hope to patients suffering from debilitating neurological conditions.

Montara Therapeutics promotes a culture of innovation and collaboration, focused on developing groundbreaking therapies for neurological diseases. The company values scientific rigor and a strong work ethic, while also fostering a supportive and inclusive environment where team members can share ideas and contribute to the company's success.